Elanco Animal Health (ELAN) - Net Assets
Based on the latest financial reports, Elanco Animal Health (ELAN) has net assets worth $6.55 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($13.36 Billion) and total liabilities ($6.81 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Elanco Animal Health (ELAN) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.55 Billion |
| % of Total Assets | 49.01% |
| Annual Growth Rate | -0.78% |
| 5-Year Change | -12.8% |
| 10-Year Change | N/A |
| Growth Volatility | 22.24 |
Elanco Animal Health - Net Assets Trend (2016–2025)
This chart illustrates how Elanco Animal Health's net assets have evolved over time, based on quarterly financial data. Also explore ELAN current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Elanco Animal Health (2016–2025)
The table below shows the annual net assets of Elanco Animal Health from 2016 to 2025. For live valuation and market cap data, see ELAN stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $6.55 Billion | +7.40% |
| 2024-12-31 | $6.10 Billion | -2.04% |
| 2023-12-31 | $6.22 Billion | -14.62% |
| 2022-12-31 | $7.29 Billion | -2.92% |
| 2021-12-31 | $7.51 Billion | -11.42% |
| 2020-12-31 | $8.48 Billion | +52.81% |
| 2019-12-31 | $5.55 Billion | +6.72% |
| 2018-12-31 | $5.20 Billion | -33.29% |
| 2017-12-31 | $7.79 Billion | +10.86% |
| 2016-12-31 | $7.03 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Elanco Animal Health's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 129.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $-141.00 Million | -2.15% |
| Other Components | $8.87 Billion | 135.48% |
| Total Equity | $6.55 Billion | 100.00% |
Elanco Animal Health Competitors by Market Cap
The table below lists competitors of Elanco Animal Health ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Huaneng Power International Inc
SHG:600011
|
$11.25 Billion |
|
Grupo Aeroportuario del Pacifico SAB De CV ADR
NYSE:PAC
|
$11.25 Billion |
|
CITIC Pacific Special Steel Group Co Ltd
SHE:000708
|
$11.26 Billion |
|
Fuzhou Rockchip Electronics Co Ltd
SHG:603893
|
$11.27 Billion |
|
DIETEREN GR. UNSP.ADR 1/2
F:DJD
|
$11.24 Billion |
|
BUDWEISER BREW.UNSP.ADR/4
F:4BB1
|
$11.20 Billion |
|
Gildan Activewear Inc.
TO:GIL
|
$11.20 Billion |
|
Zhejiang Zheneng Electric Power Co Ltd
SHG:600023
|
$11.18 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Elanco Animal Health's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,096,000,000 to 6,547,000,000, a change of 451,000,000 (7.4%).
- Net loss of 232,000,000 reduced equity.
- Other comprehensive income increased equity by 630,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-232.00 Million | -3.54% |
| Other Comprehensive Income | $630.00 Million | +9.62% |
| Other Changes | $53.00 Million | +0.81% |
| Total Change | $- | 7.40% |
Book Value vs Market Value Analysis
This analysis compares Elanco Animal Health's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.71x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.14x to 1.71x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $19.73 | $22.51 | x |
| 2017-12-31 | $21.87 | $22.51 | x |
| 2018-12-31 | $16.57 | $22.51 | x |
| 2019-12-31 | $14.98 | $22.51 | x |
| 2020-12-31 | $19.20 | $22.51 | x |
| 2021-12-31 | $15.41 | $22.51 | x |
| 2022-12-31 | $14.93 | $22.51 | x |
| 2023-12-31 | $12.64 | $22.51 | x |
| 2024-12-31 | $12.26 | $22.51 | x |
| 2025-12-31 | $13.19 | $22.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Elanco Animal Health utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.92%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 2.04x
- Recent ROE (-3.54%) is below the historical average (-3.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -0.68% | -1.64% | 0.36x | 1.15x | $-750.69 Million |
| 2017 | -3.99% | -10.75% | 0.32x | 1.15x | $-1.09 Billion |
| 2018 | 1.66% | 2.82% | 0.34x | 1.72x | $-433.25 Million |
| 2019 | 1.22% | 2.21% | 0.34x | 1.62x | $-486.79 Million |
| 2020 | -6.61% | -17.11% | 0.19x | 2.09x | $-1.41 Billion |
| 2021 | -6.43% | -10.14% | 0.29x | 2.19x | $-1.23 Billion |
| 2022 | -1.07% | -1.77% | 0.28x | 2.13x | $-806.90 Million |
| 2023 | -19.78% | -27.87% | 0.31x | 2.31x | $-1.85 Billion |
| 2024 | 5.54% | 7.61% | 0.35x | 2.07x | $-271.60 Million |
| 2025 | -3.54% | -4.92% | 0.35x | 2.04x | $-886.70 Million |
Industry Comparison
This section compares Elanco Animal Health's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $459,373,250
- Average return on equity (ROE) among peers: -63.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Elanco Animal Health (ELAN) | $6.55 Billion | -0.68% | 1.04x | $11.24 Billion |
| Aurora Cannabis Inc (ACB) | $605.09 Million | 0.26% | 0.40x | $197.35 Million |
| Akanda Corp (AKAN) | $26.90 Million | -43.34% | 0.45x | $1.51 Million |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $340.21 Million |
| Alkermes Plc (ALKS) | $1.82 Billion | 13.28% | 0.39x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $164.76 Million | -183.14% | 0.18x | $1.77 Billion |
| Amphastar P (AMPH) | $337.33 Million | 1.34% | 0.35x | $959.02 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $366.97 Million | 2.90% | 9.74x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $896.36 Million | -18.93% | 3.86x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $287.08 Million | 1.44% | 0.21x | $199.00 Million |
| ANI Pharmaceuticals Inc (ANIP) | $15.92 Million | -75.48% | 0.12x | $1.80 Billion |
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide … Read more